BlackRock’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-486,153
| Closed | -$16.5M | – | 5780 |
|
|
2025
Q4 | $16.5M | Buy |
486,153
+396,650
| +443% | +$12.3M | ﹤0.01% | 3189 |
|
|
2025
Q3 | $2.31M | Sell |
89,503
-346
| -0.4% | -$4.53K | ﹤0.01% | 4050 |
|
|
2025
Q2 | $719K | Sell |
89,849
-207,299
| -70% | -$1.58M | ﹤0.01% | 4360 |
|
|
2025
Q1 | $2.9M | Buy |
297,148
+9,832
| +3% | +$96.7K | ﹤0.01% | 3875 |
|
|
2024
Q4 | $3.63M | Sell |
287,316
-24,999
| -8% | -$318K | ﹤0.01% | 3850 |
|
|
2024
Q3 | $5.02M | Buy |
312,315
+7,336
| +2% | +$148K | ﹤0.01% | 3696 |
|
|
2024
Q2 | $7.44M | Sell |
304,979
-4,040
| -1% | -$187K | ﹤0.01% | 3532 |
|
|
2024
Q1 | $22.2M | Buy |
309,019
+2,388
| +0.8% | +$332K | ﹤0.01% | 2933 |
|
|
2023
Q4 | $61M | Buy |
306,631
+16,779
| +6% | +$2.08M | ﹤0.01% | 2353 |
|
|
2023
Q3 | $38.5M | Buy |
289,852
+18,046
| +7% | +$2.95M | ﹤0.01% | 2556 |
|
|
2023
Q2 | $40.7M | Buy |
271,806
+343
| +0.1% | +$53.4K | ﹤0.01% | 2617 |
|
|
2023
Q1 | $39.9M | Buy |
271,463
+33,522
| +14% | +$6.78M | ﹤0.01% | 2606 |
|
|
2022
Q4 | $37.7M | Sell |
237,941
-19,891
| -8% | -$3.18M | ﹤0.01% | 2661 |
|
|
2022
Q3 | $49.6M | Buy |
257,832
+759
| +0.3% | +$144K | ﹤0.01% | 2437 |
|
|
2022
Q2 | $37.5M | Buy |
257,073
+31,840
| +14% | +$4.24M | ﹤0.01% | 2683 |
|
|
2022
Q1 | $39.6M | Buy |
225,233
+49
| +0% | +$9.26K | ﹤0.01% | 2715 |
|
|
2021
Q4 | $66.2M | Sell |
225,184
-12,169
| -5% | -$3.25M | ﹤0.01% | 2469 |
|
|
2021
Q3 | $59M | Buy |
237,353
+36,270
| +18% | +$9.59M | ﹤0.01% | 2553 |
|
|
2021
Q2 | $51.1M | Buy |
201,083
+27,173
| +16% | +$5.08M | ﹤0.01% | 2688 |
|
|
2021
Q1 | $30.9M | Buy |
173,910
+912
| +0.5% | +$150K | ﹤0.01% | 2928 |
|
|
2020
Q4 | $27.3M | Buy |
172,998
+24,318
| +16% | +$5.29M | ﹤0.01% | 2841 |
|
|
2020
Q3 | $38.3M | Buy |
148,680
+5,788
| +4% | +$1.28M | ﹤0.01% | 2449 |
|
|
2020
Q2 | $33.2M | Buy |
142,892
+75,458
| +112% | +$11.7M | ﹤0.01% | 2507 |
|
|
2020
Q1 | $11.5M | Buy |
67,434
+60,064
| +815% | +$13.7M | ﹤0.01% | 2927 |
|
|
2019
Q4 | $1.63M | Buy |
+7,370
| New | +$1.36M | ﹤0.01% | 3846 |
|
BlackRock's RAPT Position: Q1 2026 in Review
BlackRock sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 486,153 shares — an estimated $16.5M sold.
BlackRock first reported a position in RAPT in Q4 2019 and held it in 25 quarters. The position peaked at $66.2M in Q4 2021. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- BlackRock reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- BlackRock sold 486,153 RAPT Therapeutics shares in Q1 2026, an estimated $16.5M.
- BlackRock first reported a position in RAPT Therapeutics in Q4 2019 and held it in 25 quarters.
- BlackRock's RAPT Therapeutics position peaked at $66.2M in Q4 2021.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.